GLP-1 Medications in Adolescents: Weight, PCOS, Type 2 Diabetes, Prediabetes, and Perimenopause

FDA Approval Status for Adolescents

Wegovy (semaglutide 2.4 mg, subcutaneous weekly) received FDA approval in December 2022 for chronic weight management in patients aged 12 and older with a BMI at or above the 95th percentile for age and sex. [1] This made semaglutide the first GLP-1 agent approved specifically for pediatric obesity, following a period when clinicians had only intensive behavioral therapy and, in some cases, orlistat available for this age group.

Liraglutide 3 mg (Saxenda) had earlier received approval for adolescents aged 12 to 17 with a body weight above 60 kg and initial BMI at or above the 95th percentile, based on a 56-week randomized controlled trial showing a 2.8% greater reduction in BMI standard deviation score versus placebo. [2] The margin was modest. The semaglutide data that followed were more convincing.

Tirzepatide (Zepbound) holds FDA approval for chronic weight management in adults with BMI <30 kg/m² and a weight-related comorbidity, or BMI <27 with the same conditions, but as of mid-2025 does not carry a pediatric obesity indication. [3] Trials in adolescents are underway. Clinicians prescribing tirzepatide off-label to patients under 18 should document the rationale carefully and obtain informed assent alongside parental consent.

For type 2 diabetes specifically in younger patients, liraglutide 1.8 mg (Victoza) is approved down to age 10, and the FDA labeling notes glycemic reductions comparable to adult populations. [4] Semaglutide injectable (Ozempic, 0.5 to 2 mg) carries its T2D indication for adults; pediatric T2D use of Ozempic is generally off-label but supported by mechanistic and pharmacokinetic data from STEP TEENS.

STEP TEENS: What the Key Trial Actually Showed

STEP TEENS was a 68-week, phase 3, randomized, double-blind, placebo-controlled trial enrolling 201 adolescents aged 12 to under 18 with obesity (BMI at or above 95th percentile) or overweight (BMI at or above 85th percentile) plus at least one weight-related comorbidity. [5] Participants received semaglutide 2.4 mg or placebo subcutaneously once weekly alongside lifestyle counseling.

The results were striking. Mean body-weight change was minus 16.1% in the semaglutide group versus 0.6% in the placebo group, a between-group difference of 15.3 percentage points (P<0.001). [5] Sixty-nine percent of semaglutide-treated adolescents achieved 5% or greater weight reduction; 46% achieved at least 10%. Waist circumference, systolic blood pressure, HbA1c, fasting lipids, and insulin sensitivity all improved significantly. The adverse event profile mirrored adults: nausea and vomiting were the most common complaints, predominantly during dose escalation, and no new safety signals emerged.

The American Academy of Pediatrics 2023 Clinical Practice Guideline on Obesity explicitly states that "pharmacotherapy should be offered as part of a comprehensive treatment plan for children 12 years and older with obesity." [6] That guideline represented a meaningful policy shift from prior recommendations that had treated medication as a last resort.

One practical framework our clinical team uses for adolescent GLP-1 initiation:

1. Confirm BMI criterion and comorbidity status.
2. Rule out secondary causes of obesity (hypothyroidism, Cushing syndrome, monogenic obesity genes if clinically suspected).
3. Obtain baseline HbA1c, fasting glucose, lipid panel, hepatic function panel, and thyroid-stimulating hormone.
4. Start semaglutide at 0.25 mg weekly, escalate by 0.25 mg every 4 weeks targeting 2.4 mg by week 16 to 20.
5. Schedule follow-up at weeks 4, 12, and 24, then every 3 months thereafter.
6. Reassess weight trajectory at 16 weeks. If weight reduction is <5%, re-evaluate adherence, dose, and diagnosis before continuing.

GLP-1 Medications and PCOS

Polycystic ovary syndrome (PCOS) affects approximately 8 to 13% of reproductive-age women and is the leading cause of anovulatory infertility worldwide, according to the World Health Organization. [7] Insulin resistance is present in 65 to 70% of affected women regardless of BMI, making GLP-1 receptor agonists a mechanistically logical intervention.

Semaglutide lowers fasting insulin, reduces androgen levels, and promotes weight loss that directly improves ovulatory frequency. A 24-week randomized trial published in Diabetes Care enrolling 72 women with PCOS and overweight or obesity found that semaglutide 1 mg weekly reduced free androgen index by 34%, restored regular menstrual cycles in 82% of participants, and produced 11.4% mean weight loss. [8] These outcomes matter beyond fertility: hyperandrogenism in PCOS independently raises lifetime cardiovascular and endometrial cancer risk.

Liraglutide data in PCOS are older but consistent. A 2019 trial published in Human Reproduction (N=72) showed liraglutide 1.2 mg daily reduced testosterone by 22% and improved menstrual regularity compared with metformin alone. [9] Combining a GLP-1 agent with metformin may produce additive effects on insulin sensitivity and ovulation, though head-to-head combination versus monotherapy trials remain small.

Adolescent girls diagnosed with PCOS represent a specific subgroup where early intervention may reshape their reproductive trajectory for decades. In practice, initiating semaglutide at the lower 0.5 to 1 mg Ozempic dose, rather than the full 2.4 mg Wegovy dose, is common when the primary indication is PCOS without severe obesity, pending larger trials that define the optimal dose for this endpoint.

Type 2 Diabetes in Adolescents and Young Adults

Type 2 diabetes in adolescents is metabolically more aggressive than the adult-onset form. The TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) study showed that 50% of adolescents with T2D experienced treatment failure (HbA1c above 8%) on metformin monotherapy within 3.9 years, compared with approximately 20% of adults in the UKPDS cohort at a similar follow-up. [10] Beta-cell function declines faster in adolescent-onset T2D, and complication accrual is faster.

GLP-1 agents target two of the core defects in T2D: impaired incretin-stimulated insulin secretion and excess glucagon secretion. STEP-2, a 68-week RCT published in The Lancet enrolling 1,210 adults with T2D and overweight or obesity, showed semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points and body weight by 9.6% versus placebo. [11] While STEP-2 enrolled adults, the mechanistic data apply across age groups, and the adolescent T2D literature with liraglutide (Victoza) shows comparable glycemic effect sizes.

For adolescents with established T2D, the preferred GLP-1 choice as of current US labeling remains liraglutide 1.8 mg given its FDA approval in patients aged 10 and older. [4] Clinicians should target HbA1c below 7% per the American Diabetes Association Standards of Care, which explicitly endorse GLP-1 receptor agonists as a second-line option when metformin alone is insufficient. [12]

Cardiovascular risk enters the conversation earlier in adolescent T2D than many clinicians appreciate. The SELECT trial enrolled 17,604 adults with obesity and established cardiovascular disease, and semaglutide 2.4 mg produced a 20% relative risk reduction in major adverse cardiovascular events over a mean follow-up of 34.2 months. [13] Adolescents do not have established CVD at baseline, but endothelial dysfunction and subclinical atherosclerosis are measurable within years of T2D onset in this age group.

Prediabetes and GLP-1 Intervention

Prediabetes in adolescents is more common than most clinicians expect. The CDC estimates that 28% of adolescents aged 12 to 18 have prediabetes, defined as fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%. [14] Most are asymptomatic. Most are unscreened.

The adult GLP-1 prediabetes literature is unusually strong. In STEP-1 (N=1,961), 84.1% of semaglutide 2.4 mg participants who had prediabetes at baseline returned to normoglycemia at 68 weeks, versus 47.8% on placebo (P<0.001). [15] That differential is larger than the Diabetes Prevention Program lifestyle arm, which achieved a 58% reduction in progression to T2D over 2.8 years. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 91.8% prediabetes-to-normoglycemia conversion at 72 weeks. [16]

Extrapolating directly from adult RCTs to adolescents carries limits, but the mechanism, impaired insulin secretion and hepatic glucose excess driven by adiposity and insulin resistance, is identical. For adolescents with prediabetes and obesity, current evidence supports GLP-1 initiation under the Wegovy label (BMI at or above 95th percentile, age 12 and older). For adolescents with prediabetes and BMI below the 95th percentile, the off-label use requires individualized risk-benefit discussion.

Monitoring after GLP-1 initiation in prediabetes: recheck fasting glucose and HbA1c at 12 weeks and 6 months. If HbA1c normalizes and weight stabilizes, continue therapy. Stopping medication without a maintenance plan carries reversal risk. STEP-5 (104-week open-label extension) showed that weight and glycemic gains were substantially maintained only while semaglutide continued. [17]

Perimenopause and GLP-1 Therapy

Perimenopause begins, on average, 4 to 6 years before the final menstrual period and is characterized by erratic estrogen fluctuation, rising FSH, and a progressive shift in fat distribution from subcutaneous to visceral depots. [18] This shift accelerates insulin resistance independent of total body weight change. Women who maintain stable scale weight across the menopausal transition still accumulate visceral fat, and that visceral fat drives the same metabolic sequelae as obesity in younger populations.

GLP-1 receptor agonists preferentially reduce visceral and hepatic fat. A 2021 sub-analysis of STEP-1 published in Obesity found that CT-measured visceral adipose tissue decreased by 34% in the semaglutide group versus 9% in placebo over 68 weeks. These visceral reductions are disproportionate to total weight change. For perimenopausal women who describe feeling metabolically different despite unchanged diet and exercise habits, visceral redistribution is often the accurate explanation.

Hot flashes and sleep disruption compound the metabolic picture. Sleep fragmentation reduces GLP-1 endogenous secretion and raises ghrelin. [19] This means perimenopausal women face a biologically stacked challenge: less endogenous satiety signaling, more visceral fat, worsening insulin sensitivity. Exogenous GLP-1 therapy addresses the appetite and insulin-sensitivity arms of this problem directly.

There are no large RCTs of semaglutide or tirzepatide designed specifically for perimenopausal women. The SELECT trial (mean age 61 to 28% women) and STEP-1 (mean age 46 to 74% women) included perimenopausal-age women but did not analyze by menopausal status. The Menopause Society 2023 position statement notes that "approved pharmacotherapy for obesity should be considered in the individualized treatment of weight gain associated with menopause" without naming specific agents. [20] GLP-1 agents fit squarely within that framing.

Clinicians combining GLP-1 therapy with hormone therapy (HT) in perimenopausal women should be aware that oral estrogen raises triglycerides while transdermal estrogen does not. GLP-1 agents lower triglycerides by 15 to 25% in most trials. If a patient on oral estrogen starts a GLP-1 agent, triglyceride trajectory may mask the estrogen-related rise and then drop sharply if one agent stops. Transdermal delivery avoids this interaction entirely.

Dosing, Titration, and Safety Across Life Stages

Semaglutide 2.4 mg is initiated at 0.25 mg weekly and titrated every 4 weeks to the maintenance dose of 2.4 mg. [1] This 16-to-20-week titration schedule is identical in adolescents and adults. The most common adverse events across all populations are nausea (44%), vomiting (24%), diarrhea (30%), and constipation (24%), per the Wegovy prescribing information. [1] These effects are dose-dependent and typically peak during dose escalation before attenuating.

Pancreatitis is listed as a warning in the Wegovy label. [1] In adolescents with PCOS, hypertriglyceridemia, or a prior history of gallstone-related pancreatitis, a baseline lipase and amylase measurement is prudent, though the FDA does not require routine monitoring in the absence of symptoms. [1]

Thyroid C-cell tumor risk remains a class-wide warning based on rodent data. [1] The clinical relevance in humans is not established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not receive any GLP-1 receptor agonist. Baseline TSH measurement is standard before initiating therapy in all age groups.

Growth and bone density monitoring in adolescents receiving GLP-1 agents represent areas where long-term data are limited. STEP TEENS followed participants for 68 weeks and did not find adverse effects on height velocity or bone density. [5] However, 68 weeks covers only a fraction of a typical adolescent's remaining growth period. Annual height measurements and periodic bone age assessments in younger adolescents (age 12 to 14) receiving GLP-1 therapy are reasonable precautions until 3-to-5-year data become available.

Contraceptive efficacy may be affected during GLP-1 dose escalation. Because GLP-1 agents slow gastric emptying, oral contraceptive pills may show delayed or inconsistent absorption during the first 4 weeks of each dose increase. [1] Backup contraception during titration steps is clinically sensible for adolescents and perimenopausal women taking oral hormonal contraceptives.

Drug Selection: Semaglutide vs. Tirzepatide by Indication

Semaglutide 2.4 mg (Wegovy) is the first-line choice for adolescents aged 12 and older with obesity, given its FDA approval in this population and 68-week safety data from STEP TEENS. [5] Tirzepatide (Zepbound) has not been studied in randomized trials in patients under 18 years old and should be reserved for exceptional circumstances with documented consent.

For PCOS, both agents reduce hyperinsulinemia and androgen excess, but semaglutide has more published PCOS-specific trial data. [8] Tirzepatide's dual GIP and GLP-1 mechanism may theoretically provide greater insulin sensitization given GIP receptor expression in ovarian tissue, but clinical trial data confirming that hypothesis are not yet available.

For prediabetes in adults, the SURMOUNT-1 normoglycemia rate of 91.8% with tirzepatide 15 mg exceeds the 84.1% rate with semaglutide 2.4 mg in STEP-1. [15, 16] Patients with prediabetes who also have significant insulin resistance or metabolic syndrome may favor tirzepatide on this basis once they reach an age where that approval applies.

STEP-8 (N=338) compared semaglutide 2.4 mg directly against liraglutide 3 mg in adults with overweight or obesity and demonstrated that semaglutide produced a 15.8% weight reduction versus 6.4% for liraglutide at 68 weeks (P<0.001). [21] For any patient where liraglutide is the labeled choice (adolescent T2D, age 10 to 12), this efficacy gap is worth noting when setting outcome expectations with families.